PNPLA3 and metabolic dysfunction-associated steatohepatitis: Genotyping for PNPLA3 could become part of the screening for patients with steatosis, as it might predict the risk for nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and cardiovascular disease.